Atwater Malick LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,964 shares of the company’s stock after acquiring an additional 1,233 shares during the quarter. Johnson & Johnson accounts for about 3.3% of Atwater Malick LLC’s portfolio, making the stock its 16th largest position. Atwater Malick LLC’s holdings in Johnson & Johnson were worth $7,124,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. Moneta Group Investment Advisors LLC raised its holdings in Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares in the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $4,609,399,000. Morgan Stanley grew its position in shares of Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Nordwand Advisors LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $785,273,000. Finally, Price T Rowe Associates Inc. MD lifted its position in Johnson & Johnson by 15.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after acquiring an additional 3,849,148 shares during the last quarter. Institutional investors and hedge funds own 67.57% of the company’s stock.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by company insiders.
Johnson & Johnson Stock Down 0.7 %
Johnson & Johnson (NYSE:JNJ – Free Report) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.67 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd were paid a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.95%. The ex-dividend date was Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 99.58%.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the company. UBS Group started coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Morgan Stanley increased their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a report on Wednesday, April 19th. Raymond James cut their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Finally, TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $171.57.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Order From U.S. Army Fuels Surge In Enovix Stock
- The Bottom Is In For Mullen Automotive
- Could Meta Be Risking Another Sell Off With Its New “Threads”?
- 2 Must-Have Specialized ETFs for the Long-Term Investor
- Inspire Medical Up 15% After Breakout, Analysts Say It’s A Buy
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
